"Elimination was predominantly through renal excretion."@en . . . . . . "approved"@en . "Olopatadin"@en . . . "Opatanol"@en . . . . . . "Thomas Bader, Hans-Ulrich Bichsel, Bruno Gilomen, Imelda Meyer-Wilmes, Mark Sundermeier, \"Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof.\" U.S. Patent US20070232814, issued October 04, 2007."@en . . . . . . "Ophthalmic use of olopatadine usually does not produce measurable plasma concentrations."@en . . . . . . . . . . "For the treatment of ocular itching associated with allergic conjunctivitis."@en . . . . . . . "Olopatadine"@en . . . "113806-05-6"@en . . . . "Olopatadina"@en . . . "Humans and other mammals"@en . . "Olopatadine is a selective histamine H1 antagonist that binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors."@en . . . . " "@en . . . . . . . . . . . . "# Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, Mukouyama A: Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002 Apr;88(4):379-97. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12046981 # Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA: The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996 Winter;12(4):389-400. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8951675 # Ohmori K, Hasegawa K, Tamura T, Miyake K, Matsubara M, Masaki S, Karasawa A, Urayama N, Horikoshi K, Kajita J, Hasegawa M, Taniguchi K, Komada T, Kawamoto Y: Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung. 2004;54(12):809-29. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15646365 # Ohmori K, Ikemura T, Kobayashi H, Mukouyama A: [Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug] Nippon Yakurigaku Zasshi. 2001 Jul;118(1):51-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11496828 # Kaliner MA, Oppenheimer J, Farrar JR: Comprehensive review of olopatadine: the molecule and its clinical entities. Allergy Asthma Proc. 2010 Mar;31(2):112-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20406593"@en . . "Olopatadinum"@en . . . . . . . "Olopatadine"@en . . . . " "@en . "3 hours"@en . . . "Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells."@en . . . .